Cybin High On Psychedelic-Based CYB003 For MDD
Updated Phase II Data Show Strong Efficacy
The company will initiate a Phase III program in mid-2024, testing the deuterated psilocybin analog as an adjunctive treatment for depression on top of SSRIs.
The company will initiate a Phase III program in mid-2024, testing the deuterated psilocybin analog as an adjunctive treatment for depression on top of SSRIs.